CRISPR THERAPEUTICS AG
|
Common Shares, par value CHF 0.03 per share
|
H17182108
|
Michael Parini
Vertex Pharmaceuticals Incorporated 50 Northern Avenue Boston, Massachusetts 02210 (617) 341-6100 |
June 6, 2019
|
CUSIP No. H17182108
|
|
13D
|
|
Page 2 of 5 Pages
|
||||||||
|
|
|
||||||||||
1.
|
|
NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
Vertex Pharmaceuticals Incorporated (“Vertex US”) |
|
|
||||||||
2.
|
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(see instructions) (a) ☐ (b) ☐ |
|
|
||||||||
3.
|
|
SEC USE ONLY
|
|
|
||||||||
4.
|
|
SOURCE OF FUNDS (see instructions)
WC |
|
|
||||||||
5.
|
|
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ☐
|
|
|
||||||||
6.
|
|
CITIZENSHIP OR PLACE OF ORGANIZATION
Massachusetts |
|
|
||||||||
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
|
|
7.
|
|
SOLE VOTING POWER
0
|
||||||||
|
8.
|
|
SHARED VOTING POWER
5,380,940 (1)
|
|||||||||
|
9.
|
|
SOLE DISPOSITIVE POWER
0
|
|||||||||
|
10.
|
|
SHARED DISPOSITIVE POWER
5,380,940 (1) |
|||||||||
11.
|
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
5,380,940 (1) |
|
|
||||||||
12.
|
|
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
(see instructions) ☐ |
|
|
||||||||
13.
|
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
10.2% (2) |
|
|
||||||||
14.
|
|
TYPE OF REPORTING PERSON (see instructions)
CO |
|
|
CUSIP No. H17182108
|
|
13D
|
|
Page 3 of 5 Pages
|
||||||||
|
|
|
||||||||||
1.
|
|
NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
Vertex Pharmaceuticals (Europe) Limited (“Vertex Europe”) |
|
|
||||||||
2.
|
|
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(see instructions) (a) ☐ (b) ☐ |
|
|
||||||||
3.
|
|
SEC USE ONLY
|
|
|
||||||||
4.
|
|
SOURCE OF FUNDS (see instructions)
WC |
|
|
||||||||
5.
|
|
CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ☐
|
|
|
||||||||
6.
|
|
CITIZENSHIP OR PLACE OF ORGANIZATION
England and Wales |
|
|
||||||||
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
|
|
7.
|
|
SOLE VOTING POWER
0 |
||||||||
|
8.
|
|
SHARED VOTING POWER
5,380,940 |
|||||||||
|
9.
|
|
SOLE DISPOSITIVE POWER
0 |
|||||||||
|
10.
|
|
SHARED DISPOSITIVE POWER
5,380,940 |
|||||||||
11.
|
|
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
5,380,940 |
|
|
||||||||
12.
|
|
CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
(see instructions) ☐ |
|
|
||||||||
13.
|
|
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
10.2% (1) |
|
|
||||||||
14.
|
|
TYPE OF REPORTING PERSON (see instructions)
OO |
|
|
CUSIP No. H17182108
|
|
13D
|
|
Page 4 of 5 Pages
|
|
|
|
Exhibit 4 |
Standstill Agreement, made and entered into as of June 6, 2019, by and between CRISPR Therapeutics AG, Vertex Pharmaceuticals Incorporated and Vertex Pharmaceuticals
(Europe) Limited.
|
CUSIP No. H17182108
|
|
13D
|
|
Page 5 of 5 Pages
|
|
|
|
VERTEX PHARMACEUTICALS INCORPORATED
|
||
/s/ Michael Parini
|
||
Michael Parini
|
||
EVP, Chief Legal and Administrative Officer
|
||
June 7, 2019
|
||
VERTEX PHARMACEUTICALS (EUROPE) LIMITED
|
||
/s/ Klas Holmlund
|
||
Klas Holmlund
|
||
Director
|
||
June 7, 2019
|
To the Company: |
CRISPR Therapeutics AG
|
With a copy to: |
Goodwin Procter LLP
|
To Vertex: |
Vertex Pharmaceuticals Incorporated
|
CRISPR Therapeutics AG
|
|||
By:
|
/s/ Rodger Novak |
||
Name: Rodger Novak
|
|||
Title: President
|
|||
VERTEX PHARMACEUTICALS INCORPORATED
|
|||
By:
|
/s/ Jeffrey Leiden |
||
Name: Jeffrey Leiden
|
|||
Title: Chairman, President and Chief Executive Officer
|
|||
VERTEX PHARMACEUTICALS (EUROPE) LIMITED
|
|||
By:
|
/s/ Klas Holmlund |
||
Name: Klas Holmlund
|
|||
Title: Director
|